Impact of Type 2 Diabetes and Postmenopausal Hormone Therapy on Incidence of Cognitive Impairment in Older Women | Zendy

Mark A. Espeland | Zendy; Roberta Dı́az Brinton | Zendy; Christina E. Hugenschmidt | Zendy; JoAnn E. Manson | Zendy; Suzanne Craft | Zendy; Kristine Yaffe | Zendy; Julie C. Weitlauf | Zendy; Leslie Vaughan | Zendy; Karen Johnson | Zendy; Claudia B. Padula | Zendy; Rebecca D. Jackson | Zendy; Susan M. Resnick | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of Type 2 Diabetes and Postmenopausal Hormone Therapy on Incidence of Cognitive Impairment in Older Women

Author(s) -

Mark A. Espeland,

Roberta Dı́az Brinton,

Christina E. Hugenschmidt,

JoAnn E. Manson,

Suzanne Craft,

Kristine Yaffe,

Julie C. Weitlauf,

Leslie Vaughan,

Karen Johnson,

Claudia B. Padula,

Rebecca D. Jackson,

Susan M. Resnick

Publication year - 2015

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc15-1385

Subject(s) - medicine , dementia , diabetes mellitus , hormone therapy , type 2 diabetes , estrogen , medroxyprogesterone acetate , incidence (geometry) , placebo , endocrinology , breast cancer , disease , cancer , physics , optics , alternative medicine , pathology

In older women, higher levels of estrogen may exacerbate the increased risk for cognitive impairment conveyed by diabetes. We examined whether the effect of postmenopausal hormone therapy (HT) on cognitive impairment incidence differs depending on type 2 diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research